The attached document contains a new Request for Proposal (RFP) from Pfizer's Global Medical Grants program. While Pfizer recognizes many institutions and healthcare professionals around the globe are prioritizing challenges associated with the COVID-19 pandemic, we are cognizant that the healthcare and patient community will continue to benefit from ongoing support for research, improvement science, and education in spite of this crisis. It is in this spirit that Pfizer will continue our grants program by publishing RFPs that have been planned for 2020. Thank you in advance for all that you are doing to improve the care of patients. Pfizer is proud to be able to support these efforts through this grants program. Please contact the Global Medical Grants team at GMG@pfizer.com if you have any questions or would like to be temporarily removed from our mailing list.

Pfizer and Lilly Announce
2020 Osteoarthritis and Osteoarthritis Pain- Virtual Learning Competitive Grant Program

I. Background

Pfizer and Lilly are collaborating to provide grant support for continuing professional education in the area of Osteoarthritis/Osteoarthritis Pain. We are committed to supporting innnovative, independent medical education for healthcare professionals. Grants via this collaboration will be funded by Pfizer, but reviewed and approved by both companies. Further information about their collaboration is available on the Pfizer grant website.

The mission of Pfizer Independent Grants for Learning & Change (GMG) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this RFP we encourage organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer and/or Lilly.

Grant applications should be submitted through Pfizer. When an RFP is issued, it is posted on the GMG website in the Grants Process section and is sent via e-mail to all registered users in our grants system. Some RFPs may also be posted on the websites of other relevant organizations.

II. Eligibility

Geographic Scope:	Global
Applicant Eligibility Criteria	• The following may apply: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project. • For projects offering continuing education credit, the requesting organization must be accredited. • More information on organizations eligible to apply directly for a grant can be found at http://www.pfizer.com/files/IGLC_OrganizationEligibility_effJuly2015.pdf.

III. Requirements

Date RFP Issued	April 22, 2020
Clinical Area	Osteoarthritis (OA) /Chronic Pain associated with OA
General Area of Interest for this RFP:	There remains unmet need in the management of osteoarthritis and chronic pain associated with osteoarthritis. Given the recent and anticipated cancelation of many medical conferences worldwide, healthcare providers will have difficulty staying current with the newest recommendations for management/guidelines of OA and the emerging data for research/therapies under development to treat OA and OA pain. Through this RFP, it is our intent to support virtual programs for HCPs on Osteoarthritis and Chronic Pain associated with OA patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data from canceled or virtual rheumatology, pain, primary care or other associated medical conferences are of particular interest. Projects that will be considered for Pfizer and Lilly support will focus on education including, but not limited to: • The impact and importance of Osteoarthritis (OA) and its disease burden and the unmet medical need in OA pain management

	- Current standard of care for OA/OA pain and its challenges - Comprehensive OA pain management – including the biopsychosocial aspects of the disease, setting functional goals and tools for individual pain and function assessment, goal setting, monitoring and tailored pain management - Comorbidities associated with chronic pain in OA (psych, etc) - The impacts of COVID-19 on Chronic Pain Osteoarthritis patients - Trends in OA management and the future of OA management - The evolution of the primary provider of Osteoarthritis - who owns OA management? - Addressing healthcare disparities - Are there best practices from other disease states we can learn from? The successful applicant will propose projects that actively engage the learner, employ innovative learning technologies, provide opportunities for learner exchange and include measurement techniques (needs assessment and outcomes data that allows for meaningful assessment of program impact). More information on principles of learning and behavior change for health professionals can be found at www.pfizer.com/files/HealthProfessionalsLearningandBehaviorChange_AFewPrinciples.pdf.
Target Audience:	Rheumatologists, Pain Specialists, Orthopedic Surgeons, Primary Care, Radiologists, Pharmacists, Psychologists, PT, NP/PA and other HCPs that manage patients with Osteoarthritis / Chronic Pain associated with Osteoarthritis
Expected Approximate Monetary Range of Grant Applications:	Individual projects requesting up to $250,000 will be considered.
Key Dates:	- RFP release date: April 22, 2020 - Grant Application due date: July 22, 2020 Please note the deadline is midnight Eastern Standard Time (e.g. New York, GMT -5). - Anticipated Grant Award Notification Date: August 2020 - Grants will be distributed following a fully executed Letter of Agreement.

	Note projects may not start until after the LOA is fully executed. • Period of Performance: Projects to begin September 2020.

How to Submit:	• Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click "Create your password".
	• In the application:
	    ○ For the question "What type of request are you submitting?" select Response to a Request for Proposal (RFP)
	    ○ For the question "Are you replying to a Request for Proposal as part of the Competitive Grant Program?" select Yes
	    ○ Select the following Competitive Grant Program Name: 2020 OA and OA Pain
	    ○ Select the following Primary Area of Interest: Chronic Pain
	• Requirements for submission:
	Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
	• If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.
	IMPORTANT: Be advised applications submitted through the wrong application type and/or after the due date will not be reviewed by the committee.

Questions:	• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Angelo Carter (Angelo.Carter@pfizer.com) or McKenna Roberts (roberts_mckenna_lee@lilly.com) with the subject line "2020 OA and OA Pain"
Review and Approval Process	• Grant requests received in response to a general RFP are reviewed by Pfizer and Lilly to make final grant decisions.
Mechanism by which Applicants will be Notified:	• All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period.

IV.   Terms and Conditions

Please take note every RFP released by Pfizer Global Medical Grants (GMG) is governed by specific terms and conditions. These terms and conditions can be reviewed here.

Appendix A
General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives	- Briefly state the overall goal of the project. - List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project	Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience	- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population. - If additional target audiences are included, please describe any planned customization of content or methods to ensure the education is relevant to these secondary audiences. In addition, please describe methods for reaching the target audience(s).
Project Design and Methods	- Describe the planned project, the educational approach, and the way the planned methods address the established need. - Education methods and design should be based on current literature. Preference will be given to applications that utilize established instructional design planning models, methods that have been shown to result in practice improvements, and/or with data on the effectiveness of other programs of the same type.
Innovation	Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes	In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan	• Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.
Anticipated Project Timeline	• Provide an anticipated timeline for your project including project start/end dates.
Additional Information	• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
Organization Detail	• Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.

Budget Narrative	• Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application
	
	• While estimating your budget please keep the following items in mind:
	
	    o Independent Medical Education Grants cannot be used to purchase therapeutic assets (prescription or non-prescription).
	    o Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.
	        ▪ At the conclusion of your program, a reconciliation of expenses is required using the original budget file submitted.